Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,310 total articles
SK Hynix faces a convergence of negative forces: worsening component and packaging shortages that will compress output and margins, tepid end-market demand that leaves little room for pricing, and a valuation that still assumes a cyclical rebound. We propose a short with defined entry, stop and targets for a mid-term horizon.
CleanSpark announced a transformational 20-year lease expected to generate $6.6B in contracted revenue (up to $11.6B with extensions). The market is enthusiastic, but recent earnings misses, negative free cash flow and elevated leverage make execution risk high. This trade targets upside if management can convert backlog into stable AI data center …
Post trades at an attractive multiple — roughly $3.86B market cap, P/E ~11.4 and EV/EBITDA ~7.8 — while generating roughly $517M of free cash flow. The balance sheet is leveraged, but steady FCF plus recent M&A positions and an underappreciated share-count reduction story could re-rate the stock. This trade aims to capture a re-rating into the $100…
Nano Labs (NA) is a sub-$50M market-cap Chinese fabless chip and distributed computing player. Recent strategic MOU, insider buying, low float and improving technicals create a fertile setup for a tactical long. This trade idea lays out entry, stop, target, catalysts, and a frank assessment of the risks.
XPeng shares have been punished on near-term noise, but delivery momentum, new product pre-sales, robotaxi progress and attractive technicals argue for a measured long. This trade idea lays out an entry at $13.76, a stop at $11.70 and a primary target of $21.00 over the next 46-180 trading days, with reasons and what to watch.
Agenus (AGEN) ripped higher on a financing that materially extends runway. The company's immuno-oncology assets, led by botensilimab/balstilimab and a growing partner network, justify a speculative long with clear risk controls. We lay out an entry, stop, targets and the thesis drivers that could make this a multi-bagger or a high-volatility loser …
Uber's core marketplaces - Mobility, Delivery and Freight - are generating durable free cash flow and improving unit economics. At roughly $72 a share, the stock offers a reasonable multiple on strong ROE and free cash flow generation. This trade targets upside back toward the $100 area while protecting downside below the 52-week low with a tight s…
Kratos (KTOS) trades near $51 after a pullback from its 52-week high. The headline price swings mask a healthier setup: strong funded backlog and liquidity, low debt, and a sizable short base that can compress on positive contract flow. This is a mid-term swing trade that buys into defense tailwinds while respecting execution and cash-flow risk.
PayPal's fundamentals - $5.5B in free cash flow, an EV/EBITDA of ~6x and a market cap near $42B - argue for valuation well above rumored strategic bids. This trade targets a disciplined long entry on weakness, with a clear stop and a 180-trading-day horizon to let strategic optionality and monetization improvements play out.
BorgWarner (BWA) has moved from deeply discounted levels a year ago to a balanced buy today. The shares offer a compelling free-cash-flow yield (~9.3%), reasonable EV/EBITDA (~7.1) and exposure to growing turbocharger and electric powertrain markets. Technical momentum is mixed, so a disciplined entry and stop make this an attractive risk/reward fo…
Oracle has been repriced lower on headline risk tied to its OpenAI deal and AI-capex worries. The market is treating it like a software name, but the balance sheet, enterprise-value math and cloud-scale economics argue this is a hyperscaler at a discount. The combination of heavy leverage, a temporary free-cash-flow hit and oversold technicals crea…
Molson Coors (TAP) trades at roughly a 16% free cash flow yield, a sub-1x price-to-book and an EV/EBITDA near 6.4. For investors willing to look past secular headwinds in beer consumption, the combination of strong free cash flow, a defensible dividend and sensible leverage dynamics supports a long trade with defined risk management.
Meta Platforms ($META) is trading off headlines about a possible in-house cloud push that spooked partners like Nebius. The market reaction looks disproportionate. With a $1.68T market cap, a P/E around 24, strong free cash flow ($48.25B), and clear technical momentum, this is a structured buying opportunity for traders willing to hold through head…
KLA offers exposure to AI-driven capex and advanced packaging demand. The stock is richly priced but backed by exceptional returns on capital, strong free cash flow and recent positive industry momentum. This trade formalizes a tactical long ahead of earnings with defined entry, stop and target and a mid-term horizon.
HCA plunged after flagging a weak respiratory season, but the balance sheet, cash flow, and valuation argue the market has priced in most of the downside. We upgrade to a tactical long: entry $367, stop $345, target $400 over a mid-term 45 trading day horizon.
Cerrado Gold (CRDOF) is trading around $1.24 with technicals showing constructive momentum and active short interest. The company's operational performance appears to be improving and can support a near-term re-rating despite a delayed Bankable Feasibility Study (BFS). This trade idea proposes a tactical long (swing) with a clear entry, stop and ta…
WhiteFiber’s 10-year, $865M colocation agreement for 40 MW of critical IT load and a $1.2B market cap create a high-upside, high-risk setup after a sharp pullback to the low $30s. We lay out a mid-term swing trade with precise entry, stop and target levels and explain the fundamental and technical picture that supports a speculative long.
Sterling Infrastructure (STRL) is a direct beneficiary of the U.S. data-center construction cycle. The company reported explosive growth in its e-infrastructure segment and sits on a roughly $5.15 billion backlog while generating meaningful free cash flow. The stock is extended from 52-week lows but remains below all-time highs; paired with a still…
Adobe's shares are trading near $222 after a painful H1 selloff. Fundamentals show strong cash flow (free cash flow $10.28B), an attractive EV/EBITDA of 9.09 and a market cap near $87.7B, leaving room for upside if Creative Cloud and AI-powered monetization accelerate. This is a mid-term swing trade that bets on feature-driven re-acceleration and m…
Trinity Capital (TRIN) is a BDC that pays a dependable monthly distribution and currently yields roughly 11.6% at the $17.65 price level. The combination of steady investment income, an attractive price-to-book and a market cap near $1.6B makes TRIN a pragmatic swing trade for income-oriented traders who can stomach BDC credit and rate risk. Sugges…
Melco is trading near the low end of its 52-week range after a tough multi-market cycle. Recent 2025 results showed group property EBITDA of $1.4 billion, $2.4 billion of liquidity and a $400 million debt paydown. With Macau momentum, operational awards, and manageable near-term maturities, MLCO is a swing trade to the long side on improving fundam…
SK hynix appears to have moved from commodity DRAM supplier toward a differentiated AI-memory play. The strategic push into higher-margin AI-optimized HBM and customer partnerships could re-rate the stock if execution follows through. This trade idea lays out an entry at $95.00, a conservative target of $145.00 and a stop at $78.00, with a primary …
Liberty Energy (LBRT) just posted an earnings surprise, directional guidance and is trading at reasonable multiples for a mid-cap energy-services group expanding into distributed power. Given a favorable news backdrop for oil and a cleaner fundamental profile, we upgrade our rating and lay out a trade plan: enter at $25.30, stop at $23.00, target $…
Aura Biosciences (AURA) is a clinical-stage oncology biote ch with a differentiated virus-like drug conjugate platform and an active Phase 2 program for belzupacap sarotalocan (bel-sar / AU-011). With market cap around $724M and enterprise value near $639M, the stock offers a tradeable setup: entry at $7.00, target $12.00, stop $5.80. Positive Phas…
Navan looks like a high-conviction tactical long today. Recent quarterly results showed a 50% jump in gross booking volume and management raised full-year revenue guidance after an earnings beat. Balance sheet liquidity and low leverage give the company runway to scale AI-enabled products that improve margins and payment revenue. That said, ongoing…
